Pramipexole for bipolar II depression: a placebo-controlled proof of concept study

Biological Psychiatry
Carlos A ZarateHusseini K Manji

Abstract

The original serotonergic and noradrenergic hypotheses do not fully account for the neurobiology of depression or mechanism of action of effective antidepressants. Research implicates a potential role of the dopaminergic system in the pathophysiology of bipolar disorder. The current study was undertaken as a proof of the concept that dopamine agonists will be effective in patients with bipolar II depression. In a double-blind, placebo-controlled study, 21 patients with DSM-IV bipolar II disorder, depressive phase on therapeutic levels of lithium or valproate were randomly assigned to treatment with pramipexole (n = 10) or placebo (n = 11) for 6 weeks. Primary efficacy was assessed by the Montgomery-Asberg Depression Rating Scale. All subjects except for one in each group completed the study. The analysis of variance for total Montgomery-Asberg Depression Rating Scale scores showed a significant treatment effect. A therapeutic response (>50% decrease in Montgomery-Asberg Depression Rating Scale from baseline) occurred in 60% of patients taking pramipexole and 9% taking placebo (p =.02). One subject on pramipexole and two on placebo developed hypomanic symptoms. The dopamine agonist pramipexole was found to have significant antid...Continue Reading

Associated Clinical Trials

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Nov 1, 1978·The British Journal of Psychiatry : the Journal of Mental Science·R C YoungD A Meyer
Jan 15, 1992·Biological Psychiatry·P L ReddyB S Rao
Feb 1, 1991·Journal of Clinical Psychopharmacology·S G Simpson, J R DePaulo
Apr 1, 1990·Archives of General Psychiatry·W H BerrettiniS Detera-Wadleigh
May 1, 1985·Journal of Affective Disorders·T Silverstone
Dec 1, 1967·The British Journal of Social and Clinical Psychology·M Hamilton
Mar 1, 1984·Acta Psychiatrica Scandinavica·M AsbergL Träskman-Bendz
Feb 1, 1995·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M Peet, S Peters
Apr 1, 1993·Journal of Affective Disorders·G ParkerK Eyers
Nov 22, 1996·Neuroscience Letters·M F PierceyM Camacho-Ochoa
Jul 1, 1997·International Clinical Psychopharmacology·P Willner
Dec 24, 1997·Psychological Medicine·P J ShahK P Ebmeier
Oct 28, 1998·Journal of Clinical Psychopharmacology·J Amsterdam
Dec 24, 1998·Journal of Clinical Psychopharmacology·J D AmsterdamC Beasley
May 1, 1999·Journal of the Neurological Sciences·J P Bennett, M F Piercey
Nov 7, 1999·The Psychiatric Clinics of North America·Z Rihmer, P Pestality
Apr 19, 2000·Journal of Clinical Psychopharmacology·C DeBattistaA F Schatzberg
May 17, 2000·Depression and Anxiety·M H CorriganD L Evans
Jun 16, 2000·Journal of Affective Disorders·J D Amsterdam, F Garcia-España
Oct 18, 2000·European Journal of Pharmacology·P S D'AquilaG Serra
May 2, 2001·Parkinsonism & Related Disorders·P M. CarveyZ D. Ling
Jun 23, 2001·Drugs & Aging·W D Le, J Jankovic
Feb 2, 2002·The American Journal of Psychiatry·Mortimer Ostow
Mar 23, 2002·Neurology·Jean P Hubble
Dec 7, 2002·CNS Drugs·Gin S MalhiShahzad Salim
Dec 14, 2002·Bipolar Disorders·Lorenzo LattanziGiovanni B Cassano
Dec 17, 2002·Proceedings of the National Academy of Sciences of the United States of America·Kevin J BlackJoel S Perlmutter
Apr 23, 2003·Biological Psychiatry·Paul E KeckSusan L McElroy
Apr 29, 2003·The Journal of Clinical Psychiatry·Joseph R CalabreseKaren D Wagner
Aug 2, 2003·The International Journal of Neuropsychopharmacology·Lewis L JuddMartin Keller
Sep 17, 2003·The International Journal of Neuropsychopharmacology·David J Muzina, Joseph R Calabrese
Nov 12, 2003·Archives of General Psychiatry·Mauricio TohenAlan Breier
Nov 26, 2003·Bipolar Disorders·Jay D Amsterdam, David J Brunswick

❮ Previous
Next ❯

Citations

Sep 4, 2010·Psychopharmacology·Patrick S JohnsonStephen C Fowler
May 25, 2012·European Archives of Psychiatry and Clinical Neuroscience·Konstantinos N FountoulakisEduard Vieta
Apr 12, 2006·Journal of Neurology·Paolo BaroneUNKNOWN Depression/Parkinson Italian Study Group
Apr 29, 2010·The Psychiatric Quarterly·Rif S El-MallakhRona J Roberts
Sep 20, 2011·The Psychiatric Quarterly·Lucas SpanembergKeila Maria Mendes Ceresér
Nov 5, 2008·Current Psychiatry Reports·Paul E Holtzheimer, Charles B Nemeroff
Aug 31, 2011·Current Psychiatry Reports·Marsal Sanches, Jair C Soares
Nov 5, 2011·Current Psychiatry Reports·Claudia F BaldassanoJordan Coello
Aug 21, 2012·Current Psychiatry Reports·Susan L McElroy, Paul E Keck
Feb 24, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Paul J CarlsonHusseini K Manji
Feb 2, 2013·CNS Spectrums·Mario Catena-Dell'OssoDonatella Marazziti
Feb 9, 2013·CNS Spectrums·Laura MusettiLiliana Dell'Osso
Oct 24, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Dara M CannonWayne C Drevets
Sep 9, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Xiaohua LiRichard C Shelton
Jan 20, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Eydie L Moses-KolkoWayne C Drevets
Jul 26, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Katherine E BurdickAnil K Malhotra
Jan 4, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sanjay J MathewDennis S Charney
Jan 7, 2011·The New England Journal of Medicine·Mark A Frye
Nov 11, 2009·Current Opinion in Psychiatry·Konstantinos N Fountoulakis
Apr 11, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M R Lemke
Aug 22, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M R Lemke
Nov 5, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Daniel P EisenbergKaren F Berman
Dec 1, 2006·Neuropsychiatric Disease and Treatment·Philip M Becker
Oct 12, 2010·CNS Drugs·Santiago Perez-Lloret, Olivier Rascol
Dec 14, 2011·Case Reports in Medicine·Birk Engmann
Feb 28, 2006·Nordic Journal of Psychiatry·Peter Skeppar, Rolf Adolfsson
Feb 26, 2016·Frontiers in Pharmacology·Sadia PervizAini Pervaiz
Jun 6, 2009·Expert Review of Neurotherapeutics·Daniel D Truong, Erik C Wolters
Apr 28, 2005·Expert Review of Neurotherapeutics·Philip B Mitchell, Gin S Malhi
Dec 22, 2009·Expert Review of Medical Devices·Rodrigo C L EdelmuthFelipe Fregni
Dec 7, 2013·Expert Review of Neurotherapeutics·Chi-Un Pae
Feb 9, 2007·Expert Review of Neurotherapeutics·Trevor R Norman, Graham D Burrows
Jul 1, 2009·Expert Review of Clinical Pharmacology·Vivek Datta, Anthony J Cleare
May 22, 2010·Expert Opinion on Emerging Drugs·Marsal SanchesJair C Soares
May 28, 2013·Expert Opinion on Drug Discovery·Nicolas HoertelPhilip Gorwood
Oct 27, 2006·Expert Opinion on Emerging Drugs·Philip B Mitchell, Gin S Malhi

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.